Privia Health is executing a provider-network expansion strategy that has accelerated revenue growth to 21.4% YoY in 2026Q2, yet gross margins remain structurally thin at 1.9%, underscoring the pass-through nature of value-based care economics. The fortress ba...
Price trend, volume and key moving averages
Trailing total returns as of 9/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 6, 2026 | $0.07+3.9% vs $0.07 | $633M+5.9% vs $597M |
Q2 2026 May 7, 2026 | $0.02-75.0% vs $0.08 | $604M+7.6% vs $561M |
Q1 2026 Feb 26, 2026 | $0.07+75.0% vs $0.04 | $541M+4.8% vs $516M |
Q4 2025 Nov 6, 2025 | $0.05-16.7% vs $0.06 | $580M+12.4% vs $517M |
Bank of New York Mellon Corp acquired a new stake in Privia Health Group, Inc. (NASDAQ: PRVA) in the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 2,892,536 shares of the company's stock, valued at approximately $74,425,000. Bank of
Deutsche Bank AG purchased a new stake in shares of Privia Health Group, Inc. (NASDAQ: PRVA) in the second quarter, according to its most recent 13F filing with the SEC. The fund purchased 234,049 shares of the company's stock, valued at approximately $6,022,000. Deutsche Bank AG owned approximately 0.19% of Privia Health Group
BlackRock Inc. acquired a new stake in shares of Privia Health Group, Inc. (NASDAQ: PRVA) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 21,402,417 shares of the company's stock, valued at approximately $550,684,000. BlackRock Inc. owned approximately
ARLINGTON, Va., Aug. 18, 2026 (GLOBE NEWSWIRE) -- Privia Health Group, Inc. (Nasdaq: PRVA) announced the appointment of Opella Ernest, M.D.
Benchmark PRVA against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Privia Health Group, Inc. (PRVA)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $19.10 | $2.41B | 106.11 | 22.26% | 1.08% | 3.11% | — | |
| $34.19 | $2.03B | -4.80 | 48.03% | -418.24% | -35.67% | — | |
| $62.07 | $30.66B | -4.56 | 19.44% | -2.63% | -23.94% | — | |
| $7.86 | $1.62B | -2124.32 | 46.06% | 0.89% | 20.02% | — | |
| $30.53 | $7.92B | -18.07 | 27.5% | 3.6% | 38.45% | — | |
| $26.57 | $4.97B | 27.11 | 13.05% | 25.48% | 16.95% | — |
Privia Health Group, Inc. (PRVA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Privia Health Group, Inc. (PRVA) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 6, 2026·SEC
Jul 7, 2026·SEC
May 22, 2026·SEC
Get notified when PRVA posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Privia Health Group, Inc. (PRVA) stock FAQ — growth, dividends, profitability & financials explained
Privia Health Group, Inc. (PRVA) reported $2.36B in revenue for fiscal year 2025. This represents a 259% increase from $657.6M in 2018.
Privia Health Group, Inc. (PRVA) grew revenue by 22.3% over the past year. This is strong growth.
Yes, Privia Health Group, Inc. (PRVA) is profitable, generating $28.1M in net income for fiscal year 2025 (1.1% net margin).
Privia Health Group, Inc. (PRVA) has a return on equity (ROE) of 3.1%. This is below average, suggesting room for improvement.
Privia Health Group, Inc. (PRVA) had negative free cash flow of $48.2M in fiscal year 2025, likely due to heavy capital investments.
